Risk sharing as application of value based pricing;Il Risk sharing come applicazione del value based pricing

PharmacoEconomics - Italian Research Articles

Volumn 12, Issue 2, 2010, Pages 71-80

  Lucioni, C ^a   Mazzi, S ^a   Polcaro, F ^a  

^a Wolters Kluwer Health Italy Ltd   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG COST; DRUG EFFICACY; HUMAN; ITALY; REVIEW; RISK MANAGEMENT;

EID: 77954479287     PISSN: 15909158     EISSN: 20356137     Source Type: Journal    
DOI: 10.1007/BF03320665     Document Type: Review

References (15)

1. Arrow KJ. Uncertainty and the welfare economics of medical care. Am Econ Rev 1963; 53: 941-73
2. Freemantle N, Hessel F. The applicability and generalizability of findings from clinical trials for health-policy decisions. Pharmacoeconomics 2009; 27: 5-10
3. de Puovourville G. Risk-Sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ 2006; 7: 155-7
4. Cook JP, Vernon JA, Manning R. Pharmaceutical risksharing agreements. Pharmacoeconomics 2008; 26: 551-6
5. Towse A, Garrison Jr LP. Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 2010; 28: 93-102
6. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Third edition. Oxford: Oxford University Press, 2005
7. McCabe C, Claxton K, Culyer A. The NICE cost-effectiveness threshold. What it is and what that means. Pharmacoeconomics 2008; 26: 733-44
8. http://www.ispor.org/PE guidelines/index.asp. Ultimo accesso aprile 2010
9. Associazione Italiana di Economia Sanitaria (AIES). Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Pharmacoeconomics-Italian Research Articles 2009; 11: 83-93
10. http://www.nice.org.uk/media/B52/A7/TAMethodsGuide UpdatedJune2008.pdf, Ultimo accesso aprile 2010
11. McCabe CJ, Stafinski T, Edlin R, et al. Access with evidence development schemes. A framework for description and evaluation. Pharmacoeconomics 2010; 28: 143-52
12. Boggild M, Palace J, Barton P, et al. Multiple sclerosis risksharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009; 339: b4677
13. Carlson JJ, Garrison Jr LP, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J Manag Care Pharm 2009; 15: 683-7
14. De Ambrosis P. Risk sharing e rimborso in base al risultato. Dialogo sui Farmaci 2008; 5: 235-7
15. Martini N. Trasferibilità clinica e sostenibilità dell'innovazione: va riequilibrato il rapporto economia-programmazione. In: Atti dell'incontro di studio "Sanità e innovazione tecnologica". Il Sole 24ORE, ottobre 2009: 35-41